Skip to main content

Advertisement

SpringerLink
Log in

Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Prophylactic use of letermovir (LMV) markedly reduces the incidence of early clinically significant cytomegalovirus (csCMV) infection within the first 100 days after allogeneic hematopoietic cell transplantation (allo-HCT), which improves transplant outcomes. However, some patients eventually develop late-csCMV infection (beyond day 100) after completing LMV prophylaxis. To assess the incidence of late-csCMV infection as well as its risk factors and impacts on transplant outcome, a total of 81 allo-HCT recipients who had not developed early csCMV infection during LMV prophylaxis were retrospectively analyzed. Among them, 23 (28.4%) patients developed late-csCMV infection (until day 180) at a median time of 131 days after transplantation and 30 days after LMV discontinuation, respectively. Late-csCMV infection was correlated with apparent delayed immune reconstitution: patients transplanted from HLA-mismatched donors (hazard ratio [HR] = 13.0, p = 0.011) or CMV-IgG-negative donors (HR = 2.39, p = 0.043) had a significantly higher risk. In this study, transplant outcomes did not differ between patients with and without late-csCMV infection. This suggests a need to clarify the efficacy of extended administration of LMV for preventing late-csCMV infection in a larger number of allo-HCT recipients, especially those with “high-risk” donors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chang YJ, Zhao XY, Huo MR, Xu LP, Liu DH, Liu KY, et al. Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol. 2012;32:268–80.

    Article  CAS  Google Scholar 

  2. Raiola AM, Dominietto A, Di Grazia C, Lamparelli T, Gualandi F, Ibatici A, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20:1573–9.

    Article  Google Scholar 

  3. Slade M, Goldsmith S, Romee R, DiPersio JF, Dubberke ER, Westervelt P, et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2017;19: e12629.

    Article  Google Scholar 

  4. Lin CH, Su YJ, Hsu CY, Wang PN, Teng CJ. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk for cytomegalovirus infection in adult patients with acute leukemia. Transpl Infect Dis. 2019;21: e13096.

    PubMed  Google Scholar 

  5. Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2014;59:473–81.

    Article  Google Scholar 

  6. Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427–38.

    Article  CAS  Google Scholar 

  7. Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation transplantation-related complication working group. Biol Blood Marrow Transplant. 2015;21:2008–16.

    Article  Google Scholar 

  8. Borst EM, Kleine-Albers J, Gabaev I, Babic M, Wagner K, Binz A, et al. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. J Virol. 2013;87:1720–32.

    Article  CAS  Google Scholar 

  9. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anti-cytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85:10884–93.

    Article  CAS  Google Scholar 

  10. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.

    Article  CAS  Google Scholar 

  11. Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leuekmia (ECIL-7). Lancet Infect Dis. 2019;19:e260–72.

    Article  Google Scholar 

  12. Lin A, Maloy M, Su Y, Bhatt V, DeRespiris L, Griffin M, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience. Transpl Infect Dis. 2019;4: e13187.

    Google Scholar 

  13. Sharma P, Gakhar N, MacDonald J, Abidi MZ, Benamu E, Bajrovic V, et al. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2020;55:780–6.

    Article  CAS  Google Scholar 

  14. Lin A, Flynn J, DeRespiris L, Figgins B, Griffin M, Lau C, et al. Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2021;27(85):e1–6.

    Google Scholar 

  15. Mori Y, Jinnouchi F, Takenaka K, Aoki T, Kuriyama T, Kadowaki M, et al. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transplant. 2021;56:853–62 (Online ahead of print).

    Article  CAS  Google Scholar 

  16. Derigs P, Radujkovic A, Schubert ML, Schnitzler P, Schoning T, Muller-Tidow C, et al. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world dara. Ann Hematol. 2021;100:2087–93 (Online ahead of print).

    Article  CAS  Google Scholar 

  17. Zamora D, Akoto B, Xie H, Kiener R, Edmison BC, Stevens-Ayers T, et al. Cytomegalovirus (CMV)-specific polyfunctional T-cell responses after letermovir (LET) prophylaxis in hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant. 2020;26:S68–9 (abstract).

    Article  Google Scholar 

  18. Bansal R, Gordillo CA, Abramova R, Assal A, Mapara MY, Pereira MR, et al. Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft-versus-host disease. Transpl Infect Dis. 2020;23: e13487 (Online ahead of print).

    PubMed  Google Scholar 

  19. Styczynski J, Tridello G, Xhaard A, Medinger M, Mielke S, Taskinen M, et al. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transplant. 2020;56(5):1171–9 (Online ahead of print).

    Article  Google Scholar 

  20. Robin C, Thiebaut A, Alain S, de Fontbrune FS, Berceanu A, D’Aveni M, et al. Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French Compassionate Program. Biol Blood Marrow Transplant. 2020;26:978–84.

    Article  CAS  Google Scholar 

  21. Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060–7.

    Article  CAS  Google Scholar 

  22. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–14.

    Article  CAS  Google Scholar 

  23. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–7.

    Article  Google Scholar 

  24. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Trasnplant. 2013;48:452–8.

    Article  CAS  Google Scholar 

  25. Yokoyama H, Kanda J, Kato S, Kondo E, Maeda Y, Saji H, et al. Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation. Bone Marrow Transplant. 2019;54:1004–12.

    Article  CAS  Google Scholar 

  26. Klein AK, Patel DD, Gooding ME, Sempowski GD, Chen BJ, Liu C, et al. T-cell recovery in adults and children following umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2001;7:454–66.

    Article  CAS  Google Scholar 

  27. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007;110:4543–51.

    Article  CAS  Google Scholar 

  28. Jameson SC. Maintaining the norm: T-cell homeostatis. Nat Rev Immunol. 2002;2:547–56.

    Article  CAS  Google Scholar 

  29. Kanda J, Chiou LW, Szabolcs P, Sempowski GD, Rizzieri DA, Long GD, et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:1664–76.

    Article  CAS  Google Scholar 

  30. Brown JA, Stevenson KE, Kin HT, Cutler C, Ballen K, McDonough SM, et al. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010;115:4111–9.

    Article  CAS  Google Scholar 

  31. Jacobson CA, Turki AT, McDonough SM, Stevenson KE, Kin HT, Kao G, et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:565–74.

    Article  CAS  Google Scholar 

  32. Clave E, Lisini D, Douay C, Giorgiani G, Busson M, Zecca M, et al. Thymic function recovery after unrelated donor cord blood or T-cell depleted HLA-haploidentical stem cell transplantation correlates with leukemia relapse. Front Immunol. 2013;4:54.

    Article  Google Scholar 

  33. Hill JA, Zamora D, Xie H, Thur LA, Delaney C, Dahlberg A, et al. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients. Blood Adv. 2021;5:3113–9.

    Article  CAS  Google Scholar 

  34. Ljungman P, Peres-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91:78–83.

    PubMed  Google Scholar 

  35. Webb BJ, Harrington R, Schwartz J, Kammerer J, Spalding J, Lee E, et al. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation. Transpl Infect Dis. 2018;20: e12961.

    Article  Google Scholar 

  36. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97:1232–40.

    Article  CAS  Google Scholar 

  37. Zhou W, Longmate J, Lacey SF, Palmer JM, Gallez-Hawkins G, Thao L, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood. 2009;113:6465–76.

    Article  CAS  Google Scholar 

  38. Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, Zaia JA, et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood. 2010;116:1655–62.

    Article  CAS  Google Scholar 

  39. Toya T, Taguchi A, Kitaura K, Misumi F, Nakajima Y, Otsuka Y, et al. T-cell receptor repertoire of cytomegalovirus-specific cytotoxic T cells after allogeneic stem cell transplantation. Sci Rep. 2020;10:22218.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the medical and nursing staff who cared for the patients at the Kyushu University Hospital and provided patients information.

Author information

Authors and Affiliations

  1. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    Yasuo Mori, Takuya Harada, Goichi Yoshimoto, Takahiro Shima, Akihiko Numata, Fumiaki Jinnouchi, Takuji Yamauchi, Yoshikane Kikushige, Yuya Kunisaki, Koji Kato, Katsuto Takenaka, Koichi Akashi & Toshihiro Miyamoto

  2. Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan

    Katsuto Takenaka

Authors
  1. Yasuo Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takuya Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Goichi Yoshimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takahiro Shima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akihiko Numata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fumiaki Jinnouchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takuji Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshikane Kikushige
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuya Kunisaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Koji Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Katsuto Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Koichi Akashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Toshihiro Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshihiro Miyamoto.

Ethics declarations

Conflict of interest

K.A. and T.M. received honoraria from MSD Co., Ltd. The other authors have no conflicts of interests to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mori, Y., Harada, T., Yoshimoto, G. et al. Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis. Int J Hematol 116, 258–265 (2022). https://doi.org/10.1007/s12185-022-03348-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-022-03348-2

Keywords

Search

Navigation